RHOT1P3

Across TCGA pan-cancer cohorts, RHOT1P3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RHOT1P3 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RHOT1P3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RHOT1P3 expression acts as an unfavorable survival marker.

LUAD and HNSC are the cancer types where RHOT1P3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.057	0.812	<.001	36	view →
HNSC	OS	Median	All	0.222	0.751	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RHOT1P3–LUAD (OS)

Open the LUAD breakdown →